Upneeq Patent Expiration

Upneeq is a drug owned by Rvl Pharmaceuticals Inc. It is protected by 12 US drug patents filed from 2020 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 16, 2039. Details of Upneeq's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324722 Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

Active
US11311515 Oxymetazoline compositions
Dec, 2039

(15 years from now)

Active
US11541036 Oxymetazoline compositions
Dec, 2039

(15 years from now)

Active
US11103482 Oxymetazoline compositions
Dec, 2039

(15 years from now)

Active
US10940138 Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

Active
US10799481 Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

Active
US11701343 Compositions and methods for treating ocular disorders
Dec, 2039

(15 years from now)

Active
US10898573 Oxymetazoline compositions
Dec, 2039

(15 years from now)

Active
US10814001 Oxymetazoline compositions
Dec, 2039

(15 years from now)

Active
US8357714 Compositions and methods for non-surgical treatment of ptosis
Aug, 2031

(6 years from now)

Active
US9867808 Compositions and methods for non-surgical treatment of Ptosis
Aug, 2031

(6 years from now)

Active
US10912765 Compositions and methods for non-surgical treatment of ptosis
Aug, 2031

(6 years from now)

Active


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Upneeq's patents.

Given below is the list of recent legal activities going on the following patents of Upneeq.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 12th Yr, Small Entity 17 Jul, 2024 US8357714
Payment of Maintenance Fee, 4th Yr, Small Entity 12 Apr, 2024 US10799481
Payment of Maintenance Fee, 4th Yr, Small Entity 12 Apr, 2024 US10814001
Recordation of Patent Grant Mailed 18 Jul, 2023 US11701343
Patent Issue Date Used in PTA Calculation 18 Jul, 2023 US11701343
Electronic Review 18 Jul, 2023 US11701343
Patent eGrant Notification 18 Jul, 2023 US11701343
Email Notification 18 Jul, 2023 US11701343
Mail Patent eGrant Notification 18 Jul, 2023 US11701343
Recordation of Patent eGrant 18 Jul, 2023 US11701343


FDA has granted several exclusivities to Upneeq. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Upneeq, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Upneeq.

Exclusivity Information

Upneeq holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Upneeq's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jul 08, 2023

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Upneeq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Upneeq's family patents as well as insights into ongoing legal events on those patents.

Upneeq's Family Patents

Upneeq has patent protection in a total of 28 countries. It's US patent count contributes only to 36.7% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click below to unlock the full patent family tree for Upneeq.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Upneeq's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 16, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Upneeq Generics:

Oxymetazoline Hydrochloride is the generic name for the brand Upneeq. 1 company has already filed for the generic of Upneeq. Check out the entire list of companies who have already received approval for Upneeq's generic

Alternative Brands for Upneeq

Upneeq which is used for correcting drooping eyelids., has several other brand drugs using the same active ingredient (Oxymetazoline Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Mayne Pharma
Rhofade
St Renatus
Kovanaze


Apart from brand drugs containing the same ingredient, some generics have also been filed for Oxymetazoline Hydrochloride, Upneeq's active ingredient. Check the complete list of approved generic manufacturers for Upneeq





About Upneeq

Upneeq is a drug owned by Rvl Pharmaceuticals Inc. It is used for correcting drooping eyelids. Upneeq uses Oxymetazoline Hydrochloride as an active ingredient. Upneeq was launched by Rvl Pharms in 2020.

Approval Date:

Upneeq was approved by FDA for market use on 08 July, 2020.

Active Ingredient:

Upneeq uses Oxymetazoline Hydrochloride as the active ingredient. Check out other Drugs and Companies using Oxymetazoline Hydrochloride ingredient

Treatment:

Upneeq is used for correcting drooping eyelids.

Dosage:

Upneeq is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.1% SOLUTION/DROPS Prescription OPHTHALMIC